Azithromycin Found to Be Comparable to Levofloxacin for the Treatment of US Travelers with Acute Diarrhea Acquired in Mexico

Javier A Adachi, Charles D. Ericsson, Zhi Dong Jiang, Margaret W. DuPont, Francisco Martinez-Sandoval, Charles Knirsch, Herbert L. DuPont

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Increased drug resistance among enteropathogens is an emergent problem in travelers' diarrhea. This randomized, double-blind trial was conducted in Guadalajara, Mexico, during the summers of 1999-2001 to compare azithromycin with levofloxacin for the treatment of travelers' diarrhea. A total of 217 US adults were randomized to receive a single oral dose of azithromycin (1000 mg; 108 persons) or levofloxacin (500 mg; 109 persons), with a follow-up period of 4 days. Three patients in each group dropped out of the study. The median time between initiation of therapy and passage of the last unformed stool (azithromycin group, 22.3 h; levofloxacin group, 21.5 h) and the number of unformed stools passed during the 4-day follow-up period (azithromycin group, 6.5; levofloxacin group, 5.5) were similar. Treatment failure occurred in 10 patients (9.5%) receiving azithromycin and 8 patients (7.5%) receiving levofloxacin. Possible minor, self-limiting adverse events occurred in 57 patients in each treatment group. Azithromycin was found to be a safe and effective alternative to levofloxacin for the treatment of acute travelers' diarrhea in US adult travelers to Mexico.

Original languageEnglish (US)
Pages (from-to)1165-1171
Number of pages7
JournalClinical Infectious Diseases
Volume37
Issue number9
DOIs
StatePublished - Nov 1 2003

Fingerprint

Levofloxacin
Azithromycin
Mexico
Diarrhea
Therapeutics
Treatment Failure
Drug Resistance

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Adachi, J. A., Ericsson, C. D., Jiang, Z. D., DuPont, M. W., Martinez-Sandoval, F., Knirsch, C., & DuPont, H. L. (2003). Azithromycin Found to Be Comparable to Levofloxacin for the Treatment of US Travelers with Acute Diarrhea Acquired in Mexico. Clinical Infectious Diseases, 37(9), 1165-1171. https://doi.org/10.1086/378746

Azithromycin Found to Be Comparable to Levofloxacin for the Treatment of US Travelers with Acute Diarrhea Acquired in Mexico. / Adachi, Javier A; Ericsson, Charles D.; Jiang, Zhi Dong; DuPont, Margaret W.; Martinez-Sandoval, Francisco; Knirsch, Charles; DuPont, Herbert L.

In: Clinical Infectious Diseases, Vol. 37, No. 9, 01.11.2003, p. 1165-1171.

Research output: Contribution to journalArticle

Adachi, JA, Ericsson, CD, Jiang, ZD, DuPont, MW, Martinez-Sandoval, F, Knirsch, C & DuPont, HL 2003, 'Azithromycin Found to Be Comparable to Levofloxacin for the Treatment of US Travelers with Acute Diarrhea Acquired in Mexico', Clinical Infectious Diseases, vol. 37, no. 9, pp. 1165-1171. https://doi.org/10.1086/378746
Adachi, Javier A ; Ericsson, Charles D. ; Jiang, Zhi Dong ; DuPont, Margaret W. ; Martinez-Sandoval, Francisco ; Knirsch, Charles ; DuPont, Herbert L. / Azithromycin Found to Be Comparable to Levofloxacin for the Treatment of US Travelers with Acute Diarrhea Acquired in Mexico. In: Clinical Infectious Diseases. 2003 ; Vol. 37, No. 9. pp. 1165-1171.
@article{569ccd7ec99043bdb1a40cd5d4016d45,
title = "Azithromycin Found to Be Comparable to Levofloxacin for the Treatment of US Travelers with Acute Diarrhea Acquired in Mexico",
abstract = "Increased drug resistance among enteropathogens is an emergent problem in travelers' diarrhea. This randomized, double-blind trial was conducted in Guadalajara, Mexico, during the summers of 1999-2001 to compare azithromycin with levofloxacin for the treatment of travelers' diarrhea. A total of 217 US adults were randomized to receive a single oral dose of azithromycin (1000 mg; 108 persons) or levofloxacin (500 mg; 109 persons), with a follow-up period of 4 days. Three patients in each group dropped out of the study. The median time between initiation of therapy and passage of the last unformed stool (azithromycin group, 22.3 h; levofloxacin group, 21.5 h) and the number of unformed stools passed during the 4-day follow-up period (azithromycin group, 6.5; levofloxacin group, 5.5) were similar. Treatment failure occurred in 10 patients (9.5{\%}) receiving azithromycin and 8 patients (7.5{\%}) receiving levofloxacin. Possible minor, self-limiting adverse events occurred in 57 patients in each treatment group. Azithromycin was found to be a safe and effective alternative to levofloxacin for the treatment of acute travelers' diarrhea in US adult travelers to Mexico.",
author = "Adachi, {Javier A} and Ericsson, {Charles D.} and Jiang, {Zhi Dong} and DuPont, {Margaret W.} and Francisco Martinez-Sandoval and Charles Knirsch and DuPont, {Herbert L.}",
year = "2003",
month = "11",
day = "1",
doi = "10.1086/378746",
language = "English (US)",
volume = "37",
pages = "1165--1171",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Azithromycin Found to Be Comparable to Levofloxacin for the Treatment of US Travelers with Acute Diarrhea Acquired in Mexico

AU - Adachi, Javier A

AU - Ericsson, Charles D.

AU - Jiang, Zhi Dong

AU - DuPont, Margaret W.

AU - Martinez-Sandoval, Francisco

AU - Knirsch, Charles

AU - DuPont, Herbert L.

PY - 2003/11/1

Y1 - 2003/11/1

N2 - Increased drug resistance among enteropathogens is an emergent problem in travelers' diarrhea. This randomized, double-blind trial was conducted in Guadalajara, Mexico, during the summers of 1999-2001 to compare azithromycin with levofloxacin for the treatment of travelers' diarrhea. A total of 217 US adults were randomized to receive a single oral dose of azithromycin (1000 mg; 108 persons) or levofloxacin (500 mg; 109 persons), with a follow-up period of 4 days. Three patients in each group dropped out of the study. The median time between initiation of therapy and passage of the last unformed stool (azithromycin group, 22.3 h; levofloxacin group, 21.5 h) and the number of unformed stools passed during the 4-day follow-up period (azithromycin group, 6.5; levofloxacin group, 5.5) were similar. Treatment failure occurred in 10 patients (9.5%) receiving azithromycin and 8 patients (7.5%) receiving levofloxacin. Possible minor, self-limiting adverse events occurred in 57 patients in each treatment group. Azithromycin was found to be a safe and effective alternative to levofloxacin for the treatment of acute travelers' diarrhea in US adult travelers to Mexico.

AB - Increased drug resistance among enteropathogens is an emergent problem in travelers' diarrhea. This randomized, double-blind trial was conducted in Guadalajara, Mexico, during the summers of 1999-2001 to compare azithromycin with levofloxacin for the treatment of travelers' diarrhea. A total of 217 US adults were randomized to receive a single oral dose of azithromycin (1000 mg; 108 persons) or levofloxacin (500 mg; 109 persons), with a follow-up period of 4 days. Three patients in each group dropped out of the study. The median time between initiation of therapy and passage of the last unformed stool (azithromycin group, 22.3 h; levofloxacin group, 21.5 h) and the number of unformed stools passed during the 4-day follow-up period (azithromycin group, 6.5; levofloxacin group, 5.5) were similar. Treatment failure occurred in 10 patients (9.5%) receiving azithromycin and 8 patients (7.5%) receiving levofloxacin. Possible minor, self-limiting adverse events occurred in 57 patients in each treatment group. Azithromycin was found to be a safe and effective alternative to levofloxacin for the treatment of acute travelers' diarrhea in US adult travelers to Mexico.

UR - http://www.scopus.com/inward/record.url?scp=0242407424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242407424&partnerID=8YFLogxK

U2 - 10.1086/378746

DO - 10.1086/378746

M3 - Article

C2 - 14557959

AN - SCOPUS:0242407424

VL - 37

SP - 1165

EP - 1171

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 9

ER -